Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Public Health, Prevention & Behaviour Change

Esketamine for Public Health, Prevention & Behaviour Change

6 papers and 0 clinical trials exploring esketamine as a treatment for public health, prevention & behaviour change.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 20% of adults experience a mental health issue in any given year worldwide.

Public Health, Prevention & Behaviour Change

Current research into psychedelics as a means of public health intervention highlights their potential in addressing various behavioural health conditions. As clinical trials expand, the implications for prevention and behaviour change are becoming increasingly apparent.

Full Public Health, Prevention & Behaviour Change profile

Academic Research

6 papers
Open Accessindividual

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial

Sensitivity analyses of the randomised ESCAPE‑TRD trial confirmed that adjunctive esketamine nasal spray was consistently superior to quetiapine extended release for achieving remission at Week 8 and remaining relapse‑free to Week 32 (relative risks 1.46–1.84, all p<0.05). Esketamine also shortened time to first and confirmed remission (hazard ratios ≈1.66–1.71), supporting the robustness of the original findings.

Published
December 2, 2024
Journal
British Journal of Psychiatry
Authors
Young, A. H., Llorca, P. M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., Mulhern-Haughey, S., Reif, A.
Open Accessindividual

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems

In a double-blind, randomised pilot study of 28 people with alcohol problems, sublingual esketamine (115.1 mg) combined with two weeks of daily mindfulness-based intervention increased psychological engagement with the practice and produced transient reductions in alcohol craving versus placebo. Esketamine also elicited greater mystical and dissociative experiences, suggesting these altered states may underlie enhanced engagement and potential therapeutic benefit.

Published
June 11, 2024
Journal
Journal of Psychopharmacology
Authors
Gent, E. M., Bryan, J. W., Cleary, M. A., Clarke, T. I., Holmwood, H. D., Nassereddine, R. O., Salway, C., Depla, S., Statton, S., Krecké, J., Morgan, C. J.
Paywallindividual

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

This open-label Phase IIIb trial (n=676) compared the efficacy of esketamine nasal spray and extended-release quetiapine, combined with an SSRI or SNRI, in patients with treatment-resistant depression (TRD). The study found that a significantly higher percentage of patients in the esketamine group achieved remission at week 8 (27.1% vs 17.6%) and had no relapse through week 32 after remission at week 8 (21.7% vs 14.1%). Adverse events were consistent with the established safety profiles of the trial treatments.

Published
October 5, 2023
Journal
New England Journal of Medicine
Authors
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Ito, T., Kambarov, Y., Llorca, P-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Fu, D. J.
Paywallindividual

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

This retrospective analysis (n=535) describes the access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD). Of the pharmacy claims for esketamine, 34.6% were approved, 46.3% were rejected, and 19.1% were abandoned. The approval rate increased to 85.2% by the second treatment session. Among 273 patients who initiated esketamine (mean age 49.3 years; 66.3% female), the mean number of sessions was 11.8 over a mean of 11.8 months, with 47.6% completing at least 8 sessions, and 93.8% of those completing induction continuing treatment.

Published
August 3, 2023
Journal
Current Medical Research and Opinion
Authors
Teeple, A., Zhdanava, M., Pilon, D., Caron-Lapointe, G., Lefebvre, P., Joshi, K.
Paywallindividual

Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study

This retrospective analysis (n=171) examined the effectiveness of esketamine in participants with treatment-resistant depression (TRD). A significant reduction in depressive symptoms was observed using the PHQ-9 and GAD-7 from baseline to last the last treatment.

Published
November 4, 2022
Journal
Future Medicine
Authors
Brendle, M., Ahuja, S., Della Valle, M., Moore, C., Thielking, P., Malone, D. C., Robison, R.
Open Accessmeta

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review

This review (2021, s=10) finds that only one of three short-term studies found favourable effects of esketamine over only antidepressants for depression, but other studies did find longer time to relapse or a longer sustained improvement in depressive symptoms.

Published
August 21, 2021
Journal
Cureus
Authors
Sapkota, A., Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., Alfonso, M.

Clinical Trials

0 trials

No clinical trials have been tagged with both Esketamine and Public Health, Prevention & Behaviour Change yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Esketamine papers Search all Public Health, Prevention & Behaviour Change trials Full Esketamine profile Full Public Health, Prevention & Behaviour Change profile